Standardized butanol fraction of WIN-34B suppresses cartilage destruction via inhibited production of matrix metalloproteinase and inflammatory mediator in osteoarthritis human cartilage explants culture and chondrocytes

BMC Complementary and Alternative Medicine

Dong-Suk Park²  Do-Young Choi¹  Jae-Dong Lee¹  Sanghoon Lee¹  Yong-Hyeon Baek²  Byung-Kwan Seo²  Jeong-Eun Huh³ 

[1] Department of Acupuncture & Moxibustion, College of Oriental Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul, 130-702, Republic of Korea;Department of Acupuncture & Moxibustion, Kyung Hee University Hospital at Gangdong, 149, Sangil-dong, Gangdong-gu, Seoul, 134-727, Republic of Korea;Oriental Medicine Research Center for Bone & Joint Disease, East–west Bone & Joint Research Institute, Kyung Hee University, 149, Sangil-dong, Gangdong-gu, Seoul 134-727, Republic of Korea

关键词: Inflammatory mediators;    Matrix proteinases;    Cartilage protection;    Standard compounds;    WIN-34B;   

Others  :  1231369
DOI  :  10.1186/1472-6882-12-256

 received in 2012-06-05, accepted in 2012-11-12,  发布年份 2012

【 摘 要 】

Background

WIN-34B is a novel Oriental medicine, which represents the n-butanol fraction prepared from dried flowers of Lonicera japonica Thunb and dried roots of Anemarrhena asphodeloides BUNGE. The component herb of WIN-34B is used for arthritis treatment in East Asian countries. The aim of this study was to determine the cartilage-protective effects and mechanisms of WIN-34B and its major phenolic compounds, chlorogenic acid and mangiferin, in osteoarthritis (OA) human cartilage explants culture and chondrocytes.

Methods

The investigation focused on whether WIN-34B and its standard compounds protected cartilage in interleukin (IL)-1β-stimulated cartilage explants culture and chondrocytes derived from OA patients. Also, the mechanisms of WIN-34B on matrix metalloproteinases (MMPs), tissue inhibitor of matrix metalloproteinases (TIMPs), inflammatory mediators, and mitogen-activated protein kinases (MAPKs) pathways were assessed.

Results

WIN-34B was not cytotoxic to cultured cartilage explants or chondrocytes. WIN-34B dose-dependently inhibited the release of glycosaminoglycan and type II collagen, increased the mRNA expression of aggrecan and type II collagen, and recovered the intensity of proteoglycan and collagen by histological analysis in IL-1β-stimulated human cartilage explants culture. The cartilage protective effect of WIN-34B was similar to or better than that of chlorogenic acid and mangiferin. Compared to chlorogenic acid and mangiferin, WIN-34B displayed equal or greater decreases in the levels of MMP-1, MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5, and markedly up-regulated TIMP-1 and TIMP-3. WIN-34B inhibited inflammatory mediators involved in cartilage destruction, such as prostaglandin E2, nitric oxide, tumor necrosis factor-alpha, and IL-1β. The phosphorylation of extracellular signal-regulated kinase, c-Jun N-terminal kinase (JNK), and p38 was significantly reduced by WIN-34B treatment, while phosphorylation of JNK was only inhibited by chlorogenic acid or mangiferin in IL-1β-stimulated chondrocytes.

Conclusions

WIN-34B is potentially valuable as a treatment for OA by virtue of its suppression of MMPs, ADAMTSs, and inflammatory mediators, and it’s up-regulation of TIMP-1 and TIMP-3 involved in the MAPK pathway.

【 授权许可】

   
2012 Huh et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Krasnokutsky S, Attur M, Palmer G, Samuels J, Abramson SB: Current concepts in the pathogenesis of osteoarthritis. Osteoarthr Cartil 2008, 16(Suppl 3):S1-S3.
• [2]Tetlow LC, Adlam DJ, Woolley DE: Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001, 44(3):585-594.
• [3]Fernandes JC, Martel-Pelletier J, Pelletier JP: The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002, 39(1–2):237-246.
• [4]Goldring MB, Goldring SR: Osteoarthritis. J Cell Physiol 2007, 213(3):626-634.
• [5]Goldring MB, Otero M: Inflammation in osteoarthritis. Curr Opin Rheumatol 2011, 23(5):471-478.
• [6]Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H: Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011, 7(1):33-42.
• [7]Samuels J, Krasnokutsky S, Abramson SB: Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis 2008, 66(3):244-250.
• [8]Thalhamer T, McGrath MA, Harnett MM: MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47(4):409-414.
• [9]Boileau C, Martel-Pelletier J, Brunet J, Schrier D, Flory C, Boily M, Pelletier JP: PD-0200347, an alpha2delta ligand of the voltage gated calcium channel, inhibits in vivo activation of the Erk1/2 pathway in osteoarthritic chondrocytes: a PKCalpha dependent effect. Ann Rheum Dis 2006, 65(5):573-580.
• [10]Geng Y, Valbracht J, Lotz M: Selective activation of the mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. J Clin Invest 1996, 98(10):2425-2430.
• [11]Liacini A, Sylvester J, Li WQ, Huang W, Dehnade F, Ahmad M, Zafarullah M: Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res 2003, 288(1):208-217.
• [12]Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE: Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 2000, 43(4):801-811.
• [13]Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA, Blair SN, Berman BM, Fries JF, Weinberger M, Lorig KR, Jacobs JJ, Goldberg V: Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med 2000, 133(9):726-737.
• [14]Dougados M: Why and how to use NSAIDs in osteoarthritis. J Cardiovasc Pharmacol 2006, 47(Suppl 1):S49-S54.
• [15]Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA: Osteoarthritis - an untreatable disease? Nat Rev Drug Discov 2005, 4(4):331-344.
• [16]Malemud CJ, Goldberg VM: Future directions for research and treatment of osteoarthritis. Front Biosci 1999, 15(4):D762-D771.
• [17]Malemud CJ: Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging 2010, 27(2):95-115.
• [18]Khalife S, Zafarullah M: Molecular targets of natural health products in arthritis. Arthritis Res Ther 2011, 13(1):102. BioMed Central Full Text
• [19]Kang M, Jung I, Hur J, Kim SH, Lee JH, Kang JY, Jung KC, Kim KS, Yoo MC, Park DS, Lee JD, Cho YB: The analgesic and anti-inflammatory effect of WIN-34B, a new herbal formula for osteoarthritis composed of Lonicera japonica Thunb and Anemarrhena asphodeloides BUNGE in vivo. J Ethnopharmacol 2010, 131(2):485-496.
• [20]Huh JE, Lee WI, Seo BK, Baek YH, Lee JD, Choi DY, Park DS: Gastroprotective and safety effects of WIN-34B, a novel treatment for osteoarthritis, compared to NSAIDs. J Ethnopharmacol 2011, 137(2):1011-1017.
• [21]Caterson B, Flannery CR, Hughes CE, Little CB: Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol 2000, 19(4):333-344.
• [22]Umlauf D, Frank S, Pap T, Bertrand J: Cartilage biology, pathology, and repair. Cell Mol Lif Sci 2010, 67(24):4197-4211.
• [23]Dudhia J: Aggrecan, aging and assembly in articular cartilage. Cell Mol Life Sci 2005, 62(19–20):2241-2256.
• [24]Fosang AJ, Little CB: Drug insight: aggrecanases as therapeutic targets for osteoarthritis. Nat Clin Pract Rheumatol 2008, 4(8):420-427.
• [25]Gouze JN, Gouze E, Popp MP, Bush ML, Dacanay EA, Kay JD, Levings PP, Patel KR, Saran JP, Watson RS, Ghivizzani SC: Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. Arthritis Res Ther 2006, 8(6):R173. BioMed Central Full Text
• [26]Deniz M, Oegema TR Jr, Schiffman EL, Look JO: The effect of exogenous glucosamine hydrochloride on the proteoglycan concentration of the articular disc of the rabbit temporomandibular joint. J Orofac Pain 2003, 17(3):251-253.
• [27]Martel-Pelletier J, Alaaeddine N, Pelletier JP: Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999, 15(4):D694-D703.
• [28]Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D: Cyclooxygenase2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 2002, 46(7):1789-1803.
• [29]Cake MA, Read RA, Appleyard RC, Hwa SY, Ghosh P: The nitric oxide donor glyceryl trinitrate increase subchondral bone sclerosis and cartilage degeneration following ovine menisectomy. Osteoarthr Cartil 2004, 12(12):974-981.
• [30]Loeser RF, Erickson EA, Long DL: Mitogen-activated protein kinases as therapeutic targets in osteoarthritis. Curr Opin Rheumatol 2008, 20(5):581-586.
• [31]Yoon SW, Chun JS, Sung MH, Kim JY, Poo H: Alpha-MSH inhibits TNF-alpha-induced matrix metalloproteinase-13 expression by modulating p38 kinase and nuclear factor kappaB signaling in human chondrosarcoma HTB-94 cells. Osteoarthr Cartil 2008, 16(1):115-124.
• [32]Chen WD, Jiang Q, Chen DY, Xu H, Zhang YF: Effects of intra-articular injection of p38 mitogen-activated protein kinase inhibitor on matrix metalloproteinase in articular cartilage of a rat model of osteoarthritis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2007, 29(6):777-781.
• [33]Sondergaard BC, Schultz N, Madsen SH, Bay-Jensen AC, Kassem M, Karsdal MA: MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation–divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation. Osteoarthr Cartil 2010, 18(3):279-288.
• [34]Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC: Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 2008, 10(3):R63. BioMed Central Full Text